Oncotarget

Research Papers:

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia

Thomas Boyer, Soizic Guihard, Christophe Roumier, Pauline Peyrouze, Fanny Gonzales, Céline Berthon, Bruno Quesnel, Claude Preudhomme, Hélène Behal, Alain Duhamel, Catherine Roche-Lestienne and Meyling Cheok _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:62377-62385. https://doi.org/10.18632/oncotarget.11481

Metrics: PDF 1900 views  |   HTML 2640 views  |   ?  


Abstract

Thomas Boyer1,2,*, Soizic Guihard2,*, Christophe Roumier1, Pauline Peyrouze2, Fanny Gonzales2, Céline Berthon2,3, Bruno Quesnel2,3, Claude Preudhomme1,2, Hélène Behal5, Alain Duhamel5, Catherine Roche-Lestienne2,4, Meyling Cheok2

1Hematology Laboratory, Biology and Pathology Center, CHRU Lille, France

2Jean-Pierre AUBERT Research Center, UMR-S1172, Lille, France

3Department of Hematology, Claude Huriez Hospital, CHRU Lille, France

4Institute of Medical Genetics, Jeanne de Flandre Hospital, CHRU Lille, France

5Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Santé Publique: Épidémiologie et Qualité des Soins, F-59000 Lille, France

*These authors have contributed equally to this work

Correspondence to:

Meyling Cheok, email: [email protected]

Keywords: acute myeloid leukemia, prognosis, CD81, tetraspanin, flow cytometry

Received: June 07, 2016     Accepted: July 28, 2016     Published: August 22, 2016

ABSTRACT

CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia (AML). We measured membrane expression of CD81 on AML cells at diagnosis, evaluated its association with AML characteristics and its influence on patient outcome after intensive chemotherapy in a cohort of 134 patients. CD81 was detected in 92/134 (69%) patients. Patients with AML expressing CD81 had elevated leukocyte count (P=0.02) and were more likely classified as intermediate or adverse-risk by cytogenetics (P<0.001). CD81 expression had a negative impact on survival (event-free survival, overall survival and relapse-free survival) in univariate (P<0.001) and in multivariate analyses (P=0.003, 0.002 and <0.001, respectively). CD81 has a negative impact on OS in patients with NPM1 mutation (P=0.01) and in patients ELN-favorable (P=0.002). In conclusion, this cell surface marker may be a new prognostic marker for diagnostic risk classification and a potential therapeutic target for drug development in AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11481